FHTX Foghorn Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1822462 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY357.3%
TTM net income YoY113.1%
TTM EPS YoY107.9%
Revenue 3-yr CAGR51.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin2.1%
Net margin8.4%
FCF margin-74.6%
EBITDA margin3.4%
Returns
ROE—
ROA4.8%
ROIC (approx.)—
Asset turnover0.57x
Leverage & solvency
Liabilities / assets107.4%
Debt / equity—
Current ratio4.24x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-8.88x
Accruals ratio47.0%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $30.91M | $22.60M | $34.16M | $19.23M | $1.32M |
| R&D expense | $85.47M | $94.53M | $109.69M | $105.62M | $80.33M |
| SG&A expense | $27.55M | $28.36M | $32.37M | $30.75M | $21.73M |
| Operating income | -$86.39M | -$102.68M | -$107.91M | -$117.14M | -$100.73M |
| Interest expense | — | — | — | — | $1.91M |
| Pretax income | — | -$86.62M | -$94.20M | -$108.88M | — |
| Income tax | $0 | $0 | $4.23M | $0 | — |
| Net income | -$74.28M | -$86.62M | -$98.43M | -$108.88M | -$101.32M |
| EBITDA | -$83.06M | -$99.56M | -$104.45M | -$113.82M | -$97.51M |
| EPS (basic) | -1.18 | -1.58 | -2.34 | -2.62 | -2.73 |
| EPS (diluted) | -1.18 | -1.58 | -2.34 | -2.62 | -2.73 |
| Weighted avg. shares (diluted) | 62.98M | 54.90M | 41.97M | 41.59M | 37.17M |
| Balance sheet | |||||
| Cash & equivalents | $80.88M | $57.16M | $82.04M | $53.92M | $102.87M |
| Current assets | $163.24M | $249.60M | $240.18M | $351.40M | $459.56M |
| PP&E, net | $1.92M | $9.96M | $12.96M | $15.31M | $17.56M |
| Total assets | $198.10M | $283.98M | $285.92M | $404.88M | $519.77M |
| Current liabilities | $59.74M | $66.99M | $58.44M | $55.20M | $48.69M |
| Long-term debt | — | — | — | — | $0 |
| Total debt | — | — | — | — | $0 |
| Total liabilities | $306.60M | $329.51M | $363.11M | $404.77M | $422.90M |
| Shareholders' equity | -$108.50M | -$45.53M | -$77.19M | $112,000 | $96.87M |
| Net debt | — | — | — | — | -$102.87M |
| Shares outstanding | 56.66M | 55.59M | 42.28M | 41.80M | 41.30M |
| Cash flow statement | |||||
| Operating cash flow | -$86.10M | -$100.41M | -$118.11M | $193.61M | -$50.25M |
| Capital expenditure | $50,000 | $906,000 | $1.22M | $1.21M | $3.31M |
| Free cash flow | -$86.15M | -$101.31M | -$119.33M | $192.40M | -$53.56M |
| Investing cash flow | $112.04M | -$29.90M | $144.45M | -$244.32M | $36.17M |
| Financing cash flow | $1.02M | $105.43M | $1.78M | $1.76M | $22.42M |
| Depreciation & amortization | $3.33M | $3.12M | $3.45M | $3.32M | $3.23M |
| Stock-based compensation | $10.40M | $11.89M | $16.19M | $14.34M | $8.38M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.